NO146763B - PROCEDURE FOR THE EXTRACTION OF IMMUNOGLOBULIN SUITABLE FOR INTRAVENOE ADMINISTRATION - Google Patents
PROCEDURE FOR THE EXTRACTION OF IMMUNOGLOBULIN SUITABLE FOR INTRAVENOE ADMINISTRATION Download PDFInfo
- Publication number
- NO146763B NO146763B NO771225A NO771225A NO146763B NO 146763 B NO146763 B NO 146763B NO 771225 A NO771225 A NO 771225A NO 771225 A NO771225 A NO 771225A NO 146763 B NO146763 B NO 146763B
- Authority
- NO
- Norway
- Prior art keywords
- immunoglobulin
- peg
- caprylic acid
- value
- precipitation
- Prior art date
Links
- 108060003951 Immunoglobulin Proteins 0.000 title claims description 17
- 102000018358 immunoglobulin Human genes 0.000 title claims description 17
- 238000000605 extraction Methods 0.000 title 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 30
- 230000003171 anti-complementary effect Effects 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims description 15
- 239000002253 acid Substances 0.000 claims description 15
- 229960002446 octanoic acid Drugs 0.000 claims description 15
- 210000002381 plasma Anatomy 0.000 claims description 14
- 238000001556 precipitation Methods 0.000 claims description 14
- 229920005862 polyol Polymers 0.000 claims description 7
- 150000003077 polyols Chemical class 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 238000001990 intravenous administration Methods 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 238000011084 recovery Methods 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 14
- 239000002202 Polyethylene glycol Substances 0.000 description 12
- 229920001223 polyethylene glycol Polymers 0.000 description 12
- 239000002244 precipitate Substances 0.000 description 12
- 229920002560 Polyethylene Glycol 3000 Polymers 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 229920005654 Sephadex Polymers 0.000 description 9
- 239000012507 Sephadex™ Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 150000007513 acids Chemical class 0.000 description 7
- 108010074605 gamma-Globulins Proteins 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000005194 fractionation Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 229940027941 immunoglobulin g Drugs 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 230000001376 precipitating effect Effects 0.000 description 3
- 238000011146 sterile filtration Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 2
- -1 polyoxypropylene Polymers 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 102000002572 Alpha-Globulins Human genes 0.000 description 1
- 108010068307 Alpha-Globulins Proteins 0.000 description 1
- 102000006734 Beta-Globulins Human genes 0.000 description 1
- 108010087504 Beta-Globulins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000659 thermocoagulation Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Description
Foreliggende oppfinnelse angår en fremgangsmåte til utvinning av immunoglobulin som har meget lav eller ingen antikomplementær aktivitet, og som er egnet til intravenøs administrering, ved fraksjonert felling av blodplasma, serum eller en immunoglobulinholdig fraksjon herav med en polykondensert di- eller polyol. The present invention relates to a method for extracting immunoglobulin which has very low or no anticomplementary activity, and which is suitable for intravenous administration, by fractional precipitation of blood plasma, serum or an immunoglobulin-containing fraction thereof with a polycondensed di- or polyol.
Immunoglobuliner, som omfatter gammaglobuliner, har terapeutisk betydning, idet de kan benyttes til fremstilling av immuniserende preparater. Immunoglobulins, which include gamma globulins, have therapeutic significance, as they can be used for the production of immunizing preparations.
Immunoglobulin finnes i blodplasma av animalsk opprinnelse hvorfra det kan utvinnes ved forskjellige fellings- og rensningsprosesser. Således kan gammaglobulin utvinnes i form av konsentrerte oppløsninger ved en metode utviklet av Cohn Immunoglobulin is found in blood plasma of animal origin from which it can be extracted by various precipitation and purification processes. Thus, gamma globulin can be extracted in the form of concentrated solutions by a method developed by Cohn
et al, jfr. J. Clin. Invest. Chem. Soc. 68, 479-75 (1946). Ifølge Cohn kan oppnås en fraksjon II som er et 16,5% konsentrat som kan injiseres intramuskulært. et al, cf. J. Clin. Invest. Chem. Soc. 68, 479-75 (1946). According to Cohn, a fraction II can be obtained which is a 16.5% concentrate that can be injected intramuscularly.
Ved den nevnte kjente fremgangsmåte dannes molekyl-aggregater av gammaglobulin som gjør preparatene uegnede til intravenøs administrering. Cohns metode omfatter således en felling med alkohol som virker vannfortrengende og kan medføre en irreversibel denaturering s-lik at globulinet blir antikomplementært. Dette har man søkt å unngå ved særlige separasjonsprosesser og/eller ved kjemisk modifisering av gammaglobulinet. In the aforementioned known method, molecular aggregates of gamma globulin are formed which make the preparations unsuitable for intravenous administration. Cohn's method thus includes a precipitation with alcohol which acts to displace water and can lead to an irreversible denaturation such that the globulin becomes anticomplementary. This has been tried to be avoided by special separation processes and/or by chemical modification of the gamma globulin.
Det kjennes således en forbedret fraksjoneringsprosess, hvorved gammaglobulinet utfelles fra blodplasma ved hjelp av polyetylenglykol (PEG) som fellingsmiddel, jfr. US-patent 3.415.804. Derved unngås den uønskede denaturering, men renheten av det utfelte produkt er utilfredsstillende. An improved fractionation process is thus known, whereby the gamma globulin is precipitated from blood plasma using polyethylene glycol (PEG) as a precipitating agent, cf. US Patent 3,415,804. Thereby, the unwanted denaturation is avoided, but the purity of the precipitated product is unsatisfactory.
PEG-felling er også beskrevet i US-patent 3.7 63.135 og 3.869.436, men fører dog, som påvist nedenfor, ikke til et immunoglobulin med tilstrekkelig lav antikomplementær aktivitet. PEG precipitation is also described in US patent 3.7 63,135 and 3,869,436, but, as demonstrated below, does not lead to an immunoglobulin with sufficiently low anticomplementary activity.
Ifølge norsk patent 137.861 kan denne fellingsprosess forbedres ved i stedet for polyetylenglykol å anvende en blokk-kopolymer av etylenoksyd og polyoksypropylenpolymer av en nærmere angitt art og ved å overholde bestemte fellingsbetingelser. According to Norwegian patent 137,861, this precipitation process can be improved by using, instead of polyethylene glycol, a block copolymer of ethylene oxide and polyoxypropylene polymer of a more specifically specified type and by observing specific precipitation conditions.
Det er på denne måte mulig å forbedre utbyttet ved utvinning av gammaglobulin. De utfelte produkter har dog ikke i alle tilfeller tilfredsstillende renhet og tilstrekkelig lav In this way, it is possible to improve the yield when extracting gamma globulin. However, the precipitated products are not in all cases of satisfactory purity and sufficiently low
antikomplementær aktivitet. anticomplementary activity.
Foreliggende oppfinnelse er basert på den iakttagelse at fellingen av immunoglobuliner, også kalt gammaglobuliner, The present invention is based on the observation that the precipitation of immunoglobulins, also called gamma globulins,
i suksessive trinn, ved hjelp av polyetylenglykol eller en annen polykondensert di- eller polyol, kan gjøres vesentlig mer spesifikk hvis det under i det minste én av fellingene med den polykondenserte di- eller polyol som ytterligere fellingsmiddel tilsettes en alkansyre med 6-9 karbonatomer, fortrinnsvis kaprylsyre. Derved fjernes bl.a. fibrinogen og lipoproteiner. in successive steps, using polyethylene glycol or another polycondensed di- or polyol, can be made substantially more specific if during at least one of the precipitations with the polycondensed di- or polyol as additional precipitant, an alkanoic acid with 6-9 carbon atoms is added, preferably caprylic acid. This removes, among other things, fibrinogen and lipoproteins.
Anvendelsen av lavere alkansyrer, så som kaprylsyre, ved plasmafraksjonering er også tidligere beskrevet. Således anvendes kaprylsyre i DE off.skrift 2.433.209 som stabilisator for albumin og visse andre proteiner under et termokoagulerings-trinn for å fraskille ikke varmestabile proteiner. Anvendelse som felningsmiddel for immunoglobulin er ikke omtalt. The use of lower alkanoic acids, such as caprylic acid, in plasma fractionation has also been previously described. Thus caprylic acid is used in DE official publication 2,433,209 as a stabilizer for albumin and certain other proteins during a thermocoagulation step in order to separate heat-stable proteins. Use as a precipitating agent for immunoglobulin is not discussed.
I Rev. Fr. Etud. Clin. Biol. 1969, 14, s. 1054-58 anvendes karpylsyre som felningsmiddel for andre proteiner enn immunoglobulin som blir tilbake i den overliggende væske. In Rev. Fr. Etude. Clin. Biol. 1969, 14, pp. 1054-58, carpylic acid is used as a precipitating agent for proteins other than immunoglobulin that remain in the overlying liquid.
Det har således ikke tidligere vært foreslått ved plasma-fraks jonering å anvende PEG eller andre polyoler som felningsmiddel i kombinasjon med kaprylsyre eller andre C^-Cg alkansyrer . It has thus not previously been proposed for plasma fractionation to use PEG or other polyols as a thickening agent in combination with caprylic acid or other C₁-Cg alkanoic acids.
Ved fremgangsmåten ifølge oppfinnelsen som er basert på ovennevnte felningsmiddelkombinasjon, oppnås på enkel måte renset immunoglobulin av en overraskende høy renhet og i høyt utbytte, og som har tilstrekkelig lav antikomplementær aktivitet slik at det kan administreres intravenøst. Utbyttet er like høyt som det er mulig å oppnå ved de beste av de ovennevnte kjente metoder. With the method according to the invention, which is based on the above-mentioned combination of agents, purified immunoglobulin of a surprisingly high purity and in high yield is obtained in a simple way, and which has sufficiently low anticomplementary activity so that it can be administered intravenously. The yield is as high as it is possible to achieve by the best of the above known methods.
En særlig effektiv rensning oppnås når felningen med alkansyren skjer ved en pH-verdi på 3-7, fortrinnsvis 4,5-5,5. A particularly effective purification is achieved when the precipitation with the alkanoic acid takes place at a pH value of 3-7, preferably 4.5-5.5.
Foreliggende fremgangsmåte kan anvendes i forbindelse med en vilkårlig polykondensert di- eller polyglykol så som polyetylenglykol med varierende molekylvekt, f.eks. 2000-12000, fortrinnsvis 4-6000, eller polypropylenglykol. Også kopolymerer av etylenoksyd med propylenoksyd eller polyetere kan anvendes. The present method can be used in connection with any polycondensed di- or polyglycol such as polyethylene glycol with varying molecular weight, e.g. 2000-12000, preferably 4-6000, or polypropylene glycol. Copolymers of ethylene oxide with propylene oxide or polyethers can also be used.
Som alkansyre kan anvendes en vilkårlig mono- eller poly-alkansyre med 6-9 karbonatomer, fortrinnsvis kaprylsyre. Eksempler på andre egnede alkansyrer er kapronsyrer og nonansyre. Any mono- or poly-alkanoic acid with 6-9 carbon atoms can be used as alkanoic acid, preferably caprylic acid. Examples of other suitable alkanoic acids are caproic acids and nonanoic acid.
Også forgrenede alkansyrer kan anvendes. Anvendes alkan- Branched alkanoic acids can also be used. Used alkane-
syrer med 9 karbonatomer, kan disse hensiktsmessig inneholde ytterligere én eller flere karboksylgrupper, hvorved vann-oppløseligheten økes. Samme virkning oppnås ved anvendelse av alkansyrer med andre substituenter, f.eks. én eller flere hydroksylgrupper eller aminogrupper. acids with 9 carbon atoms, these can appropriately contain one or more carboxyl groups, whereby the water solubility is increased. The same effect is achieved by using alkanoic acids with other substituents, e.g. one or more hydroxyl groups or amino groups.
Den immunoglobulinhoIdige oppløsning iblandes hensiktsmessig 1-8 vekt% polyetylenglykol eller en annen polykondensert diol eller polyol samt 0,1-5 vekt% kaprylsyre eller en annen alkansyre med 6-9 karbonatomer. The immunoglobulin-containing solution is suitably mixed with 1-8% by weight polyethylene glycol or another polycondensed diol or polyol and 0.1-5% by weight caprylic acid or another alkanoic acid with 6-9 carbon atoms.
Fremgangsmåten ifølge oppfinnelsen skal i det følgende illustreres nærmere ved hjelp av noen eksempler. In the following, the method according to the invention will be illustrated in more detail with the help of some examples.
Eksempel 1 Example 1
415 ml humant blodplasma inneholdende 10 g immunoglobulin pr. liter plasma innstilles på en pH-verdi på 5,0. Det tilsettes PEG 3000 til en konsentrasjon på 6%, og oppløsningen får stå i 45 minutter. Bunnfallet som hovedsakelig består av fibrinogen, frasentrifugeres og væskefasen innstilles på en pH-verdi på 7,0. Efter tilsetning av mer PEG 3000 for å oppnå en konsentrasjon på 12% får blandingen stå i 45 minutter. Blandingen sentrifugeres, og væskefasen inneholdende albumin og a- og 3-globulin fjernes. Bunnfallet som består av urent immunoglobulin, gjenoppløses i en 0,9% natriumkloridoppløsning for å oppnå en proteinkonsentrasjon på ca. 4%. Oppløsningen filtreres til klarhet på et Seitz EK-filter. Til den dannede oppløsning settes 5 g kaprylsyre og 30 g PEG 30OO pr. liter oppløsning, og den innstilles på en pH-verdi på 4,9. Efter henstand i 2 timer ved 20°C sentrifugeres blandingen, og væskefasen filtreres for å oppnå en klar oppløsning. Denne opp-løsning innstilles på pH 7,0, og det tilsettes PEG 3000 til en konsentrasjon på 12% PEG. Derved utfelles rent immunoglobulin som utvinnes ved sentrifugering og tørring. Utbyttet av produktet er 60%. Renheten bestemt ved DISC PAGE (med 5% poly-akrylamid), viser i det vesentlige bare to bånd som svarer til henholdsvis IgG ig IgM. Analysen er utført ved anvendelse av 500 i^g produkt. 415 ml of human blood plasma containing 10 g of immunoglobulin per liter of plasma is set to a pH value of 5.0. PEG 3000 is added to a concentration of 6%, and the solution is allowed to stand for 45 minutes. The precipitate, which mainly consists of fibrinogen, is centrifuged off and the liquid phase is adjusted to a pH value of 7.0. After adding more PEG 3000 to achieve a concentration of 12%, the mixture is allowed to stand for 45 minutes. The mixture is centrifuged, and the liquid phase containing albumin and α- and β-globulin is removed. The precipitate, which consists of impure immunoglobulin, is redissolved in a 0.9% sodium chloride solution to achieve a protein concentration of approx. 4%. The solution is filtered to clarity on a Seitz EK filter. To the resulting solution, add 5 g of caprylic acid and 30 g of PEG 30OO per liter of solution, and it is set to a pH value of 4.9. After standing for 2 hours at 20°C, the mixture is centrifuged, and the liquid phase is filtered to obtain a clear solution. This solution is adjusted to pH 7.0, and PEG 3000 is added to a concentration of 12% PEG. This precipitates pure immunoglobulin, which is recovered by centrifugation and drying. The yield of the product is 60%. The purity determined by DISC PAGE (with 5% polyacrylamide) essentially shows only two bands corresponding to IgG and IgM respectively. The analysis was carried out using 500 µg of product.
Ved Grabar og Williams immunoelektroforese under anvendelse av kaninantistoff mot total humant serumprotein, finnes i det- By Grabar and Williams immunoelectrophoresis using rabbit antibody against total human serum protein, there are
vesentlige bare tre buer som svarer til henholdsvis IgG, essentially only three arcs corresponding to IgG, respectively,
IgM og IgA. IgM and IgA.
Det rensede produkt kan om ønsket omdannes til et intravenøst injiserbart preparat ved oppløsning i 0,9% saltvann til en proteinkonsentrasjon på ca. 5%. Preparatet utmerker seg ved at det har en meget lav anikomplementær aktivitet, og er av den grunn særlig velegnet til intravenøs administrering. The purified product can, if desired, be converted into an intravenously injectable preparation by dissolving in 0.9% saline to a protein concentration of approx. 5%. The preparation is distinguished by the fact that it has a very low anicomplementary activity, and is therefore particularly suitable for intravenous administration.
Til sammenligning gjentas fremgangsmåten ovenfor med den forandring at kaprylsyren utelates. Denne prosess svarer til den som er beskrevet i US-patent 3.7 63.135. For comparison, the above procedure is repeated with the change that the caprylic acid is omitted. This process corresponds to that described in US patent 3.7 63,135.
Det antikomplementære innhold i de to preparater måles efter Frommhagen og Fudenberg, J. Immunology 89^, 336-343 (1962), hvorved preparatet fortynnes inntil det akkurat kan påvises antikomplementær aktivitet. I preparatet fremstilt ifølge eksempel 1 er det antikomplementære innhold så lavt at det ikke kan påvises i preparatet uten fortynning. Preparatet fremstilt uten kaprylsyre har et innhold som svarer til at det akkurat kan påvises antikomplementært innhold ved en fortynning på 1:10. I de ordinære Cohns felte immunoglobulinpreparater er innholdet så høyt at det svarer til en fortynning på ca. 1:100. The anticomplementary content in the two preparations is measured according to Frommhagen and Fudenberg, J. Immunology 89^, 336-343 (1962), whereby the preparation is diluted until anticomplementary activity can be precisely detected. In the preparation prepared according to example 1, the anticomplementary content is so low that it cannot be detected in the preparation without dilution. The preparation produced without caprylic acid has a content that corresponds to the fact that anticomplementary content can be detected exactly at a dilution of 1:10. In the ordinary Cohn's field immunoglobulin preparations, the content is so high that it corresponds to a dilution of approx. 1:100.
Eksempel 2 Example 2
Fremgangsmåten ifølge eksempel 1 gjentas med den forandring at det humane blodplasma erstattes med plasma fra svin. The procedure according to example 1 is repeated with the change that the human blood plasma is replaced with pig plasma.
Eksempel 3 Example 3
Fremgangsmåten ifølge eksempel 1 gjentas med den forandring at det istedenfor humant blodplasma anvendes blodserum. The procedure according to example 1 is repeated with the change that blood serum is used instead of human blood plasma.
Eksempel 4 Example 4
100 1 plasma eller serum blandes med 100 1 600 g/l PEG 3000 oppløsning. pH-verdien innstilles på 6,5. Bunnfallet frasentrifugeres og gjenoppløses i 100 1 destillert vann tilsatt 0,015 M NaCl. Det tilsettes 40 g PEG 3000 pr. liter og 5 g kaprylsyre pr. liter. pH-verdien innstilles på 5,0. Blandingen får stå i 45 minutter og bunnfallet frasentrifugeres. Til sentrifugatet settes ytterligere 40 g PEG 3000 pr. liter. pH-verdien innstilles på 7,5. Bunnfallet frasentrifugeres og 100 1 plasma or serum is mixed with 100 1 600 g/l PEG 3000 solution. The pH value is set to 6.5. The precipitate is centrifuged off and redissolved in 100 1 of distilled water to which 0.015 M NaCl has been added. 40 g of PEG 3000 is added per liter and 5 g of caprylic acid per litres. The pH value is set to 5.0. The mixture is allowed to stand for 45 minutes and the precipitate is centrifuged off. A further 40 g of PEG 3000 per litres. The pH value is set to 7.5. The precipitate is centrifuged off and
oppløses igjen i destillert vann med 0,002M NaCl. Oppløsningen klarfUtreres (f.eks. "Seitz" EK-filter). Proteinkonsentrasjonen skal være 50-100 g/l. Det tilsettes 20 g "DEAE-Sephadex" A25 dissolve again in distilled water with 0.002M NaCl. The solution is clarified (e.g. "Seitz" EK filter). The protein concentration should be 50-100 g/l. 20 g of "DEAE-Sephadex" A25 is added
pr. 100 g protein. Efter 1 times henstand under omrøring frafiltreres "DEAE-Sephadex". Behandlingen med "DEAE-Sephadex" gjentas. Efter sterilfiltrering oppnås et immunoglobulin G preparat som er fritt for antikomplementær aktivitet og anvendelig til intravenøs administrering. per 100 g of protein. After 1 hour's rest under stirring, the "DEAE-Sephadex" is filtered off. The treatment with "DEAE-Sephadex" is repeated. After sterile filtration, an immunoglobulin G preparation is obtained which is free of anticomplementary activity and usable for intravenous administration.
Eksempel 5 Example 5
(Sammenligningseksempel med PEG-felning uten tilsetning av kaprylsyre) (Comparison example with PEG precipitation without the addition of caprylic acid)
1000 ml plasma blandes med 1000 ml 450 g/l PEG 3000 opp-løsning. pH-verdien innstilles på 6,5. Bunnfallet fra-sentrif ugeres og oppløses igjen i 1000 ml destillert vann tilsatt 0,015M NaCl. Det tilsettes 40 g PEG 3000 pr. liter. pH-verdien innstilles på 5,0. Blandingen får stå i 45 minutter, og bunnfallet frasentrifugeres. Til sentrifugatet settes ytterligere 40 g PEG 3000 pr. liter. pH-verdien innstilles på 7,5. Bunnfallet frasentrifugeres og gjenoppløses i destillert vann med 0,002M NaCl. Oppløsningen klarfiltreres (f.eks. 1000 ml of plasma is mixed with 1000 ml of 450 g/l PEG 3000 solution. The pH value is set to 6.5. The precipitate from centrifugation is separated and dissolved again in 1000 ml of distilled water with 0.015M NaCl added. 40 g of PEG 3000 is added per litres. The pH value is set to 5.0. The mixture is allowed to stand for 45 minutes, and the precipitate is centrifuged off. A further 40 g of PEG 3000 per litres. The pH value is set to 7.5. The precipitate is centrifuged off and redissolved in distilled water with 0.002 M NaCl. The solution is clearly filtered (e.g.
"Seitz" EK-filter). Proteinkonsentrasjonen innstilles til 50 g/l. Det tilsettes 20 g "DEAE-Sephadex" A 25 pr. 100 g protein. Efter 1 times henstand under omrøring frafiltreres "DEAE-Sephadex". Behandlingen med "DEAE-Sephadex" gjentas. Efter sterilfiltrering oppnås et immunoglobulin G preparat, hvis antikomplementære aktivitet er bestemt nedenfor. "Seitz" EK filter). The protein concentration is set to 50 g/l. 20 g "DEAE-Sephadex" A 25 is added per 100 g of protein. After 1 hour's rest under stirring, the "DEAE-Sephadex" is filtered off. The treatment with "DEAE-Sephadex" is repeated. After sterile filtration, an immunoglobulin G preparation is obtained, the anticomplementary activity of which is determined below.
Eksempel 6 Example 6
(Sammenligningseksempel med fraksjonering ved hjelp av kaprylsyre i det sentrale felningstrinn) (Comparison example with fractionation using caprylic acid in the central folding step)
1000 ml plasma blandes med 1000 ml 600 g/l PEG 3000-oppløsning. pH-verdien innstilles på 6,5. Bunnfallet frasentrifugeres og gjenoppløses i 1000 ml destillert vann tilsatt 0,015M NaCl. Det tilsettes 5 g kaprylsyre pr. liter. pH-verdien innstilles på 5,0. Blandingen får stå i 45 minutter, og bunnfallet frasentrifugeres. Til sentrifugatet settes ytterligere 80 g PEG 3000 pr. liter. pH-verdien innstilles på 7,5. Bunnfallet frasentrifugeres og gjenoppløses i destillert vann med 1000 ml of plasma is mixed with 1000 ml of 600 g/l PEG 3000 solution. The pH value is set to 6.5. The precipitate is centrifuged off and redissolved in 1000 ml of distilled water to which 0.015 M NaCl has been added. 5 g of caprylic acid is added per litres. The pH value is set to 5.0. The mixture is allowed to stand for 45 minutes, and the precipitate is centrifuged off. A further 80 g of PEG 3000 per litres. The pH value is set to 7.5. The precipitate is centrifuged off and redissolved in distilled water with
0,002 M NaCl. Oppløsningen klarfiltreres (f.eks. "Seitz" EK-filter). Proteinkonsentrasjonen innstilles til 50 g/l. Det tilsettes 20 g "DEAE-Sephadex" A 25 pr. 100 g protein. Efter 1 times henstand under omrøring frafiltreres "DEAE-Sephadex". Behandlingen med "DEAE-Sephadex" gjentas. Efter sterilfiltrering oppnås et immunoglobulin G preparat hvis antikomplementære aktivitet er bestemt nedenfor. 0.002 M NaCl. The solution is clearly filtered (e.g. "Seitz" EK filter). The protein concentration is set to 50 g/l. 20 g "DEAE-Sephadex" A 25 is added per 100 g of protein. After 1 hour's rest under stirring, the "DEAE-Sephadex" is filtered off. The treatment with "DEAE-Sephadex" is repeated. After sterile filtration, an immunoglobulin G preparation is obtained whose anticomplementary activity is determined below.
Preparater fremstilt i henhold til eksemplene 4, 5 og Preparations prepared according to examples 4, 5 and
6 ovenfor ble undersøkt for antikomplementær aktivitet efter Frommhagen og Fudenberg, loe. eit. Sammenligningen viste nedenstående verdier for den antikomplementære titer, idet det bemerkes at målemetodens undergrense er 1 6 above was examined for anticomplementary activity according to Frommhagen and Fudenberg, loe. one. The comparison showed the following values for the anticomplementary titer, noting that the measurement method's lower limit is 1
Av disse resultater fremgår det klart at den ved fremgangsmåten anvendte kombinasjon medfører en dramatisk reduksjon av den antikomplementære titer i forhold til PEG og kaprylsyre anvendt separat. - Betydningen av en lav antikomplementær titer er forøvrig fremhevet av D. Gislason et al. VOX SANA 34:143-148 (1978). It is clear from these results that the combination used in the method results in a dramatic reduction of the anticomplementary titer in relation to PEG and caprylic acid used separately. - The importance of a low anticomplementary titer is also highlighted by D. Gislason et al. VOX SANA 34:143-148 (1978).
Claims (2)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK162876AA DK139056B (en) | 1976-04-06 | 1976-04-06 | Method for recovering immunoglobulin suitable for intravenous administration. |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO771225L NO771225L (en) | 1977-10-07 |
| NO146763B true NO146763B (en) | 1982-08-30 |
| NO146763C NO146763C (en) | 1982-12-08 |
Family
ID=8106680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO771225A NO146763C (en) | 1976-04-06 | 1977-04-05 | PROCEDURE FOR THE EXTRACTION OF IMMUNOGLOBULIN SUITABLE FOR INTRAVENOE ADMINISTRATION |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | USRE31268E (en) |
| JP (1) | JPS52122620A (en) |
| AR (1) | AR211890A1 (en) |
| AU (1) | AU511474B2 (en) |
| BE (1) | BE852995A (en) |
| CA (1) | CA1072444A (en) |
| CH (1) | CH628813A5 (en) |
| DD (1) | DD129451A5 (en) |
| DE (1) | DE2713817A1 (en) |
| DK (1) | DK139056B (en) |
| ES (1) | ES457482A1 (en) |
| FI (1) | FI61191C (en) |
| FR (1) | FR2347379A1 (en) |
| GB (1) | GB1551865A (en) |
| HU (1) | HU175511B (en) |
| IL (1) | IL51782A (en) |
| IT (1) | IT1075148B (en) |
| NL (1) | NL7703572A (en) |
| NO (1) | NO146763C (en) |
| SE (1) | SE7703843L (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5625114A (en) * | 1979-08-07 | 1981-03-10 | Green Cross Corp:The | Preparation of human gamma globulin |
| US4590002A (en) * | 1984-12-10 | 1986-05-20 | Ortho Diagnostic Systems, Inc. | Methods for preparation of highly purified, gamma globulins free of hepatitis-B-virus infectivity |
| FR2578425B1 (en) * | 1985-03-07 | 1988-06-10 | Nal Transfusion Sanguine Centr | IMMUNOGLOBULIN PREPARATIONS HAVING HIGH TITLES OF ANTI-ALLERGENIC BLOCKING ANTIBODIES, THEIR PREPARATION AND THEIR APPLICATIONS FOR THE TREATMENT OF ALLERGIES |
| FR2632308B1 (en) * | 1988-06-07 | 1991-08-16 | Fondation Nale Transfusion San | PROCESS AND PLANT FOR THE CONTINUOUS FRACTIONATION OF ANIMAL OR HUMAN PLANT PROTEINS |
| CA1308023C (en) * | 1988-07-29 | 1992-09-29 | William Austin James Mcauley | Immunoglobulin extraction utilizing properties of colloidal solutions |
| US5525519A (en) * | 1992-01-07 | 1996-06-11 | Middlesex Sciences, Inc. | Method for isolating biomolecules from a biological sample with linear polymers |
| US5367054A (en) * | 1993-04-12 | 1994-11-22 | Stolle Research & Development Corp. | Large-scale purification of egg immunoglobulin |
| WO2005113604A2 (en) * | 2004-05-14 | 2005-12-01 | Hematech, Llc | Methods for immunoglobulin purification |
| US20060226086A1 (en) * | 2005-04-08 | 2006-10-12 | Robinson Thomas C | Centrifuge for blood processing systems |
| US9109015B2 (en) * | 2006-11-01 | 2015-08-18 | Biogen Ma Inc | Method of isolating biomacromolecules using low pH and divalent cations |
| BRPI0911249A2 (en) * | 2008-04-16 | 2017-05-23 | Biogen Idec Inc | Biomacromolecules isolation method using polyalkylene glycol and transition metals |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3100737A (en) * | 1958-02-05 | 1963-08-13 | Auerswald Wilhelm | Method of preparing a plasma protein solution free of active hepatitis virus and product produced thereby |
| NL286954A (en) * | 1962-01-03 | |||
| NL6702923A (en) * | 1966-04-06 | 1967-10-09 | ||
| US3916026A (en) * | 1968-09-19 | 1975-10-28 | Biotest Serum Institut Gmbh | Method for the preparation of gamma-globulin suitable for intravenous use |
| US3869436A (en) * | 1971-06-01 | 1975-03-04 | Statens Bakteriologiska Lab | Method for fractionating plasma proteins using peg and ion-exchangers |
| US3770631A (en) * | 1971-06-29 | 1973-11-06 | Baxter Laboratories Inc | Clarification of blood serum and plasma |
| JPS5620287B2 (en) * | 1972-06-19 | 1981-05-13 | ||
| US3880989A (en) * | 1973-01-30 | 1975-04-29 | Baxter Laboratories Inc | Production of antisera comprising fractionating plasma or serum with an ethylene oxide-polyoxypropylene block copolymer |
| US3808189A (en) * | 1973-03-15 | 1974-04-30 | American Cyanamid Co | Isolation of gamma globulin preparations enriched in iga and igm using polyethylene glycol |
| JPS5417002B2 (en) * | 1974-02-18 | 1979-06-27 | ||
| CA1064396A (en) * | 1975-02-18 | 1979-10-16 | Myer L. Coval | Fractional precipitation of gamma globulin with polyethylene glycol |
| DE2527064C3 (en) * | 1975-06-18 | 1979-11-15 | Biotest-Serum-Institut Gmbh, 6000 Frankfurt | Process for the production of an intravenous native human immunoglobulin preparation with a natural half-life and unchanged antibody activity compared to the starting material |
| US4021540A (en) * | 1975-07-28 | 1977-05-03 | Ortho Diagnostics Inc. | Preparation of a hepatitis B immune globulin and use thereof as a prophylactic material |
| JPS5234918A (en) * | 1975-09-06 | 1977-03-17 | Biotest Serum Institut Gmbh | Production of gmmaglobulin suitable for dosing into vein |
| US4075193A (en) * | 1976-11-26 | 1978-02-21 | Parke, Davis & Company | Process for producing intravenous immune globulin |
| US4124576A (en) * | 1976-12-03 | 1978-11-07 | Coval M L | Method of producing intravenously injectable gamma globulin |
-
1976
- 1976-04-06 DK DK162876AA patent/DK139056B/en not_active IP Right Cessation
-
1977
- 1977-03-29 BE BE176213A patent/BE852995A/en not_active IP Right Cessation
- 1977-03-29 DE DE19772713817 patent/DE2713817A1/en not_active Withdrawn
- 1977-03-30 IL IL51782A patent/IL51782A/en unknown
- 1977-03-31 IT IT21982/77A patent/IT1075148B/en active
- 1977-03-31 AR AR267073A patent/AR211890A1/en active
- 1977-03-31 GB GB13575/77A patent/GB1551865A/en not_active Expired
- 1977-04-01 SE SE7703843A patent/SE7703843L/en not_active Application Discontinuation
- 1977-04-01 HU HU77NO212A patent/HU175511B/en unknown
- 1977-04-01 NL NL7703572A patent/NL7703572A/en not_active Application Discontinuation
- 1977-04-02 ES ES457482A patent/ES457482A1/en not_active Expired
- 1977-04-04 AU AU23910/77A patent/AU511474B2/en not_active Expired
- 1977-04-04 DD DD7700198240A patent/DD129451A5/en unknown
- 1977-04-05 FI FI771071A patent/FI61191C/en not_active IP Right Cessation
- 1977-04-05 CH CH428777A patent/CH628813A5/en not_active IP Right Cessation
- 1977-04-05 CA CA275,585A patent/CA1072444A/en not_active Expired
- 1977-04-05 FR FR7710326A patent/FR2347379A1/en active Granted
- 1977-04-05 NO NO771225A patent/NO146763C/en unknown
- 1977-04-06 JP JP3858877A patent/JPS52122620A/en active Pending
-
1981
- 1981-08-13 US US06/292,386 patent/USRE31268E/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| NO771225L (en) | 1977-10-07 |
| IL51782A (en) | 1980-12-31 |
| FI771071A (en) | 1977-10-07 |
| NO146763C (en) | 1982-12-08 |
| GB1551865A (en) | 1979-09-05 |
| HU175511B (en) | 1980-08-28 |
| CH628813A5 (en) | 1982-03-31 |
| FI61191C (en) | 1982-06-10 |
| DK139056B (en) | 1978-12-11 |
| FR2347379A1 (en) | 1977-11-04 |
| IT1075148B (en) | 1985-04-22 |
| DK162876A (en) | 1977-10-07 |
| USRE31268E (en) | 1983-06-07 |
| JPS52122620A (en) | 1977-10-15 |
| BE852995A (en) | 1977-07-18 |
| AU2391077A (en) | 1978-10-12 |
| AR211890A1 (en) | 1978-03-31 |
| DD129451A5 (en) | 1978-01-18 |
| DK139056C (en) | 1979-05-21 |
| NL7703572A (en) | 1977-10-10 |
| AU511474B2 (en) | 1980-08-21 |
| DE2713817A1 (en) | 1977-10-27 |
| IL51782A0 (en) | 1977-05-31 |
| SE7703843L (en) | 1977-10-07 |
| CA1072444A (en) | 1980-02-26 |
| FI61191B (en) | 1982-02-26 |
| FR2347379B1 (en) | 1981-11-20 |
| ES457482A1 (en) | 1978-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4216205A (en) | Process of preparing a serum protein composition for intravenous application | |
| CA2155630C (en) | Low temperature albumin fractionation using sodium caprylate as a partitioning agent | |
| CA1074698A (en) | Method of collecting anti-hemophilic factor viii from blood and blood plasma | |
| US4164495A (en) | Method of recovering immunoglobulin using a polyol and an alkanoic acid | |
| DK166763B1 (en) | IMMUNOGLOBULIN-G-CONTAINING FRACTION | |
| US3808189A (en) | Isolation of gamma globulin preparations enriched in iga and igm using polyethylene glycol | |
| US4371520A (en) | Process for preparing immunoglobulin suitable for intravenous injection | |
| NO146763B (en) | PROCEDURE FOR THE EXTRACTION OF IMMUNOGLOBULIN SUITABLE FOR INTRAVENOE ADMINISTRATION | |
| Felton | Concentration of pneumococcus antibody | |
| EP0249483B1 (en) | Method of producing substantially pure albumin | |
| EP0035616B1 (en) | Production of immunoglobulin having a high monomer content | |
| US4670544A (en) | Process for the manufacture of the cold insoluble globulin and pharmaceutical preparation containing it | |
| NO169875B (en) | PROCEDURE FOR PREPARING A CONCENTRATE OF THE ANTI-HEMOFILE FACTOR VIII | |
| EP0123375B1 (en) | Gamma-globulin preparation for intravenous administration | |
| US20170198009A1 (en) | Method for the preparation of immunoglobulins | |
| NO137861B (en) | PROCEDURE FOR THE PREPARATION OF A VERY READABLE GAP PROCEDURE FOR THE PREPARATION OF A VERY SOLUBLE MMAGLOBULIN GAMMAGLOBULIN | |
| US4197238A (en) | Method of preparation of human albumin using polyethylene glycol | |
| JPS6242887B2 (en) | ||
| EP0078331B1 (en) | Process for preparing immunoglobulin suitable for intravenous injection | |
| AU2016231646B2 (en) | Method for the preparation of immunoglobulins | |
| WO1988008004A1 (en) | Extraction of factor viii | |
| JP6370853B2 (en) | Method for preparing immunoglobulin | |
| RU1829938C (en) | Method of purification of gamma-globulin used for intravenous administration | |
| TWI712612B (en) | Method for the preparation of immunoglobulins solution | |
| CA1172166A (en) | Process for preparing immunoglobulin suitable for intravenous injection |